Phoenix Financial Ltd. Makes New $724,000 Investment in The Cooper Companies, Inc. $COO

Phoenix Financial Ltd. bought a new stake in shares of The Cooper Companies, Inc. (NASDAQ:COO – Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 12,814 shares of the medical device company’s stock, valued at approximately $724,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Danske Bank A S lifted its position in shares of Cooper Companies by 170.8% in the third quarter. Danske Bank A S now owns 267,236 shares of the medical device company’s stock valued at $15,107,000 after acquiring an additional 168,542 shares in the last quarter. Allworth Financial LP boosted its position in shares of Cooper Companies by 3.1% during the 3rd quarter. Allworth Financial LP now owns 14,073 shares of the medical device company’s stock valued at $796,000 after acquiring an additional 424 shares during the last quarter. Fisher Asset Management LLC boosted its position in shares of Cooper Companies by 19.6% during the 3rd quarter. Fisher Asset Management LLC now owns 11,807 shares of the medical device company’s stock valued at $667,000 after acquiring an additional 1,937 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of Cooper Companies by 292.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 554,352 shares of the medical device company’s stock valued at $31,338,000 after acquiring an additional 413,067 shares during the last quarter. Finally, Eurizon Capital SGR S.p.A. grew its holdings in shares of Cooper Companies by 57.8% in the third quarter. Eurizon Capital SGR S.p.A. now owns 382,178 shares of the medical device company’s stock valued at $21,605,000 after purchasing an additional 140,008 shares in the last quarter. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Walter Rosebrough, Jr. acquired 3,000 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The shares were bought at an average price of $54.29 per share, with a total value of $162,870.00. Following the completion of the transaction, the director directly owned 20,000 shares in the company, valued at $1,085,800. This trade represents a 17.65% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Lawrence Kurzius bought 10,000 shares of Cooper Companies stock in a transaction on Wednesday, September 16th. The stock was purchased at an average price of $54.93 per share, with a total value of $549,300.00. Following the completion of the acquisition, the director directly owned 31,099 shares of the company’s stock, valued at $1,708,268.07. This represents a 47.40% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 34,701 shares of company stock worth $1,880,039 in the last three months. 2.08% of the stock is owned by insiders.

Cooper Companies News Summary

Investors following COO have been watching these news items:

Cooper Companies Stock Down 1.2%

Shares of COO opened at $61.88 on Tuesday. The firm has a market capitalization of $11.77 billion, a P/E ratio of 21.12, a P/E/G ratio of 2.44 and a beta of 0.83. The Cooper Companies, Inc. has a 12-month low of $51.01 and a 12-month high of $89.83. The company has a current ratio of 1.22, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23. The firm has a fifty day moving average price of $58.33 and a 200-day moving average price of $68.06.

Cooper Companies (NASDAQ:COO – Get Free Report) last posted its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.12 by $0.03. The company had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The firm’s revenue was up .5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Equities research analysts expect that The Cooper Companies, Inc. will post 4.53 earnings per share for the current year.

Cooper Companies announced that its Board of Directors has approved a stock repurchase plan on Wednesday, September 9th that allows the company to repurchase $3 billion in outstanding shares. This buyback authorization allows the medical device company to reacquire up to 22.7% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Bank of America downgraded shares of Cooper Companies from a “buy” rating to a “neutral” rating and decreased their price target for the company from $80.00 to $65.00 in a research note on Thursday, September 10th. Wall Street Zen downgraded shares of Cooper Companies from a “buy” rating to a “hold” rating in a report on Saturday, September 12th. Mizuho set a $75.00 price target on Cooper Companies and gave the stock an “outperform” rating in a research report on Thursday, September 10th. JPMorgan Chase & Co. decreased their price objective on Cooper Companies from $71.00 to $58.00 and set a “neutral” rating on the stock in a research report on Thursday, September 10th. Finally, Robert W. Baird set a $61.00 target price on Cooper Companies and gave the stock a “neutral” rating in a report on Thursday, September 10th. Four research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $68.60.

Read Our Latest Analysis on COO

Cooper Companies Profile

(Free Report)

CooperCompanies is a global medical device company focused on vision care and women’s health. It serves customers in markets around the world through two primary businesses: CooperVision and CooperSurgical. CooperVision develops and sells contact lenses, including products for daily wear, astigmatism, presbyopia and myopia management. Its offerings include lenses made from silicone hydrogel and other materials, as well as specialty lens options. CooperSurgical provides products and services for women’s health and fertility care.

Featured Stories

Want to see what other hedge funds are holding COO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Cooper Companies, Inc. (NASDAQ:COO – Free Report).

Institutional Ownership by Quarter for Cooper Companies (NASDAQ:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.